Studies | EBMT

Top

Study type

Disease

Group

Type of transplant / Cell therapy

Text

Language

Impact of hematological response after Immunosuppressive Treatment on Quality of Life in Aplastic Anemia (subanalysis of the RACE trial)

Retrospective Studies

Bone marrow failure

Severe Aplastic Anaemia Working Party (SAAWP)

Type de traitement

Immunosuppressive Treatment (IST)

Investigateur principal

Iris Lommerse, Jennifer Tjon, Stijn Halkes

Efficacité et sécurité des inhibiteurs de points de contrôle immunitaire après transplantation allogénique de cellules souches hématopoïétiques dans le lymphome de Hodgkin classique en rechute/réfractaire

Études rétrospectives

Lymphome non hodgkinien (LNH)

Lymphoma Working Party (LWP)

Type de traitement

Investigateur principal

Dr. Liudmila Fedorova

Efficacy and safety of checkpoint inhibitors after allogeneic hematopoietic cell transplantation in relapsed/refractory classic Hodgkin lymphoma

Retrospective Studies

Non-Hodgkin’s Lymphoma (NHL)

Lymphoma Working Party (LWP)

Type de traitement

Investigateur principal

Dr. Liudmila Fedorova

Long-term outcomes of PTCy vs. ATG in MRD, MUD, MMUD

Études rétrospectives

Toutes les maladies

Complications Working Party (CWP)

Type de traitement

Investigateur principal

Hélène Schoemans

CVC and anticoagulation survey in HCT and CAR-T

Toutes les maladies

Complications Working Party (CWP)

Type de traitement

Investigateur principal

Retrospective analysis of Autologous and Allogeneic Hematopoietic TRansplantation in Extra Nodal Digestive Peripheral T-cell Lymphoma.

Retrospective Studies

Non-Hodgkin’s Lymphoma (NHL)

Lymphoma Working Party (LWP)

Type de traitement

Investigateur principal

Olivier TOURNILHAC

Analyse rétrospective des transplantations autologues et allogéniques dans le lymphome périphérique à cellules T extra-nodal digestif

Études rétrospectives

Lymphome non hodgkinien (LNH)

Lymphoma Working Party (LWP)

Type de traitement

Investigateur principal

Olivier TOURNILHAC

Impact of TKI discontinuation in CML patients who have previously restarted TKI following allogeneic SCT

Retrospective Studies

Chronic Myeloid Leukaemia (CML)

Chronic Malignancies Working Party (CMWP)

Type de traitement

Investigateur principal

Hugues de Lavallade

Analysis of Characteristics, Outcome and Risk Factors of Patients with Myelodysplastic Syndrome undergoing a Second Allogeneic Transplantation after Relapse from First AlloSCT

Retrospective Studies

Myelodysplastic (MDS) or MDS/MPN

Chronic Malignancies Working Party (CMWP)

Type de traitement

Investigateur principal

Giuliano Filippini Velazquez/Christoph Schmid

Development of a prognostic model for survival after allogeneic hematopoietic cell transplantation (allo-HCT) in patients with myelodysplastic neoplasms (MDS) using machine learning

Études rétrospectives

Syndrome Myélodysplasique (MDS) ou MDS/MPN

Chronic Malignancies Working Party (CMWP)

Type de traitement

Investigateur principal

Donal P. McLornan, Carmelo Gurnari, Adrián Mosquera Orgueira, Marie Robin

Development of a prognostic model for estimation of survival after allogeneic hematopoietic cell transplantation (allo-HCT) in patients Chronic Myelomonocytic Leukaemia utilizing Machine Learning

Retrospective Studies

Myelodysplastic (MDS) or MDS/MPN

Chronic Malignancies Working Party (CMWP)

Type de traitement

Investigateur principal

Marie Robin, Adrián Mosquera Orgueira, Francesco Onida, Carmelo Gurnari, Donal P. McLornan

A Retrospective analysis of transplantation outcome for individuals with Advanced Systemic Mastocytosis (Adv-SM): Aggressive Systemic Mastocytosis (ASM), SM with associated hematologic disease (SM-AHD), Mast-cell leukemia (MCL) and Mast cell Sarcoma (MCS)

Retrospective Studies

Myeloproliferative Neoplasm (MPN)

Chronic Malignancies Working Party (CMWP)

Type de traitement

Investigateur principal